Skip to main content
Market snapshot: . Prices may have changed since this snapshot.
Events
GroupKALSHI
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
Reported volume
K 1.8K contracts
Events
1
Markets
1

Current odds

Snapshot from

As of Nov 22, 2026, 3:00 PM UTC, the highest-priced outcome on Kalshi is a full approval or an accelerated approval at 75.5%.

Kalshi

  1. a full approval or an accelerated approval75.5%

Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.

AI Analysis

Trader mode: Market mechanics, assumptions and risks

K 1.8K contracts

Reported volume · provider units

1

Saved contracts

0

Same-question pairs

Source snapshot: Nov 22, 2026, 3:00 PM UTC

This analysis was written from an earlier market snapshot, so its prices may be older than the odds above.

Snapshot observed Nov 11, 2026, 12:00 AM UTC. This analysis describes that snapshot and is not a live news update.

What the contract measures

The contract asks what the FDA's decision on Saroglitazar by Zydus Therapeutics will be in 2026 [1]. According to the saved rules, a full approval or an accelerated approval resolves to Yes. A denial (CRL issued), a withdrawal by the sponsor, a conditional approval, or no decision being issued resolves to No [1]. The excerpt also states that the market will close early if the FDA issues a decision on Saroglitazar before Jan 1, 2027 [1]. The drug is described as being evaluated for primary biliary cholangitis in the EPICS-III trial [1].

Reading the snapshot

The saved snapshot was observed at Nov 11, 2026, 12:00 AM UTC and retrieved at Nov 11, 2026, 12:52 AM UTC [1]. These prices describe that observation window, not a live quote. The Yes outcome was priced at 0.745 and the No outcome at 0.255 [1]. These are snapshot prices, not executable quotes or verified probabilities.

The contract is listed as active with an end date of Jan 8, 2027, 3:00 PM UTC [1]. However, the same provider excerpt says "Listed end time: not supplied." [1] These entries conflict, so readers should check the provider page before relying on any closing time. The end date should also not be read as an announced FDA decision date, because the supplied material does not give one.

The sample contains one market from one provider event. Coverage reports one included market out of one total, and partialSample is false [1]. The sample warning states that all saved markets are included but does not establish that the provider lists every possible real-world outcome [1]. With only this contract present, no comparison with other platforms or other outcomes is possible from this evidence.

What remains uncertain

The evidence does not explain why the prices sit where they do. It also does not provide trading volume, liquidity, or the number of participants holding either view. The supplied material contains no FDA decision, sponsor announcement, or recent news about Saroglitazar. The saved rules refer to a 2026 decision, but no further timing details are supplied. Readers should check the current contract page and any official regulatory communications directly.

References

  1. Kalshi: FDA decision: Saroglitazar by Zydus Therapeutics (in 2026). Provider data observed Nov 11, 2026, 12:00 AM UTC.

AI-generated analysis based on market data. Not financial advice.

Saved Nov 11, 2026 UTC

This article was written from an earlier market snapshot and may be out of date. Use the dated market data and provider rules above for current information.

Overview

This PredictPedia entry covers a Kalshi event asking how the U.S. Food and Drug Administration (FDA) will decide on saroglitazar, a drug developed by Zydus Therapeutics, during 2026 [1]. The event is titled "FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)" and is categorized under financials [1]. The contract is a yes or no question about the type of FDA decision. Under the listed rules, it resolves to Yes if the FDA's decision is a full approval or an accelerated approval [1]. It resolves to No if the decision is a denial (a complete response letter, or CRL), a withdrawal by the sponsor, or a conditional approval, or if no decision is issued [1]. The rules also state that the market will close early if the FDA issues a decision on saroglitazar before January 1, 2027 [1]. The saved market record lists an end date of January 8, 2027 at 15:00 UTC [1]. That date appears in the contract data and is not an announced FDA date. Saroglitazar is described as an oral small-molecule drug that acts on two molecular targets, PPAR-alpha and PPAR-gamma, which together regulate how the body handles fats and sugars [1]. The source states that it is being evaluated in the EPICS-III trial as a treatment for primary biliary cholangitis, a liver disease that differs from the drug's original metabolic indications [1]. The market's yes and no prices are snapshots taken at the observation time and are not executable quotes or verified probabilities. A price should not be read as a confirmed chance of approval.

Historical Context

The source states that saroglitazar is sold under the brand name Lipaglyn in India and was originally associated with metabolic indications [1]. It also states that the drug is now being evaluated in the EPICS-III trial for primary biliary cholangitis, a liver disease distinct from those original uses [1]. The supplied evidence does not describe the drug's wider regulatory history.

Why It Matters

The contract measures whether the FDA's 2026 decision on saroglitazar will be a full or accelerated approval, which would resolve to Yes, or a different outcome, which would resolve to No [1]. Because a conditional approval, a withdrawal, a CRL, or no decision all resolve to No, the wording of the rules determines what counts as a Yes [1]. The contract's expected close is also tied to whether the FDA acts before January 1, 2027 [1].

Snapshot context

The latest published provider snapshot for this topic was observed on 2026-11-11 at 00:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]

Frequently Asked Questions

What counts as a Yes resolution?

According to the listed rules, the market resolves to Yes if the FDA's decision on saroglitazar is a full approval or an accelerated approval [1].

Does a conditional approval resolve the contract?

A conditional approval resolves the market to No under the listed rules [1].

What happens if the FDA issues no decision in 2026?

The rules state that the market resolves to No if no decision is issued [1]. The source also says the market closes early if a decision is issued before January 1, 2027 [1].

Does the yes price show the probability of approval?

No. The price is a snapshot from the provider data and is not a verified probability or an executable quote. The rules themselves define the resolution criteria [1].

Was this helpful?
Saved Nov 11, 2026 UTC

AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.

Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

KalshiFinancials
FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

K 75.66 contracts
What will the FDA's decision be on Lorundrostat by Mineralys Therapeutics on or before December 22, 2026?Yes 83.5%
1 mktNext deadline Dec 23, 2026 UTC
KalshiFinancials
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

K 4.2K contracts
What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?Yes 88.5%
1 mktNext deadline Jan 1, 2027 UTC
KalshiFinancials
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)

K 944.1 contracts
What will the FDA's decision be on BBP-418 by Ml Bio Solutions Inc. in 2026?Yes 89.5%
1 mktNext deadline Jan 1, 2027 UTC
KalshiFinancials
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

K 41.42 contracts
What will the FDA's decision be on Ralinepag by United Therapeutics on or before June 24, 2027?Yes 79.5%
1 mktNext deadline Jun 25, 2027 UTC
KalshiHealth
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

K 11.2K contracts
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before April 2027)Yes 83.5%
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before 2027)Yes 45%
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before December)Yes 8%
3 mktsNext deadline Dec 1, 2026 UTC
KalshiHealth
When will Trump nominate an FDA commissioner?

When will Trump nominate an FDA commissioner?

K 1.6K contracts
Will someone be nominated for FDA commissioner before Jan 1, 2028?Yes 83.5%
Will someone be nominated for FDA commissioner before Oct 1, 2027?Yes 77.5%
Will someone be nominated for FDA commissioner before Jul 1, 2027?Yes 70.5%
+4 moreNext deadline Dec 1, 2026 UTC

Market Insights

Price gaps of 2 pp+

0

Same-question pairs

0

No outcomes on this page have been reviewed as the same question on both platforms yet.

Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.

Trade This Market